"Providing adequate anticoagulation therapy for patients with AF undergoing cardio-version is important. With warfarin, patients will often move in and out of the therapeutic range for optimal ...

Bayer's Xarelto® (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism (PE) and the Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE in the EU Blood clots obstructing blood flow in ...

Older adults taking Bayer AG's blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious bleeding and stroke compared to those taking ...

Credit: Thinkstock. At the 2016 American Society of Hematology (ASH) Annual Meeting, researchers from Janssen and Bayer presented data showing that cancer patients treated with Xarelto (rivaroxaban) ...

Bayer and Johnson & Johnson’s Janssen Research & Development have acknowledged that their Xarelto ® (rivaroxaban) has failed a Phase III trial assessing the blockbuster anticoagulant in patients with ...

First approval for Bayer's new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct ...

(Reuters) - A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the first trial to flow out of thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drugmakers ...

The quality and depth of clinical trials of the blood-thinner Xarelto could be a key issue when the first trials over the drug begin in Philadelphia courtrooms. With the first trial of more than 800 ...

Lawyers for patients who are suing two big drug makers who market a popular blood-clotting drug say the companies withheld important information from a letter published recently in a major medical ...

(Reuters) -Older adults taking Bayer AG's blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious bleeding and stroke compared to ...